,,iv #aai? ,,congress #a/ ,session ,h4 ,,res4 #ejg ,,9 ,,! ,,h\se ,,( ,,repres5tatives ,june #ab1 #bjbe,mr4 ,bilirakis submitt$ ! foll[+ resolution2 :i* 0 ref]r$ to ! ,committee on ,en]gy & ,comm]ce ,,resolution ,express+ support = ! designation ( ,june #aj z ,,fsgs ,aw>5ess ,day4 ,:]eas approximately #a 9 #g ,am]ican adults h *ronic kidney disease1 & ! ?ird lead+ cause ( *ronic kidney disease is glom]ulonephritis1 (t5 caus$ by r>e kidney diseases su* z focal segm5tal glom]uloscl]osis 7,,fsgs72 ,:]eas focal segm5tal glom]uloscl]osis is a condition ref]r+ to ! sc>r+ 9 ! kidneys1 (t5 lead+ to a difficult j\rney t c 9 _m cases result 9 kidney failure1 requir+ dialysis1 transplant1 & (t5 cycles ( remissions & relapse2 ,:]eas #ej p]c5t ( pati5ts ) ,,fsgs require dialysis or a kidney transplant )9 #e-aj ye>s ( _! diagnosis2 ,:]eas ,,fsgs is a sev]e disease because x (t5 progresses rapidly to kidney failure & ev5 = pati5ts ) prim>y ,,fsgs :o receive a kidney transplant2 ,:]eas ,,fsgs c recur 9 _! transplant$ kidney up to #ej p]c5t ( ! "t2 ,:]eas ,,fsgs recurr5ce c happ5 quickly po/transplant1 sometimes h\rs to days1 & increases ! recurr5ce risk 9 a future graft to #hj to #ajj p]c5t2 ,:]eas ,,fsgs is a burd5 on our heal? c>e sy/em1 ) a #bjai /udy e/imat+ t ,,fsgs co/s ,m$icaid1 ,m$ic>e1 & private heal? insurance ab\t #b1jjj1jjj1jjj annually 9 direct m$ical co/s1 n includ+ indirect & quality ( life co/s2 ,:]eas1 accord+ to ! ,ra,da,r ,database1 r>e kidney diseases l ,,fsgs make up j #e to #aj p]c5t ( *ronic kidney disease pati5ts b acc\nt = approximately #cj p]c5t ( kidney failure2 ,:]eas _m pati5ts face delays 9 be+ diagnos$ ) ,,fsgs1 due bo? to ! difficulty ( ! r>e disease diagno/ic odyssey1 :i* av]ages #e to #g ye>s1 & *all5ges 9 access+ nephrology c>e t specializes 9 r>e kidney diseases1 ( :i* !re is curr5tly a %ortage 9 ! ,unit$ ,/ates2 ,:]eas ,,fsgs disproportionately impacts m9ority populations1 includ+ ,african ,am]icans1 (t5 occurr+ at a rate #d to #e times high] ?an ,:ite ,am]icans2 ,:]eas1 because ( c]ta9 v>iants ( ! ,,apol#a g5e t significantly increase ! risk ( develop+ ,,fsgs & o!r kidney diseases1 & because ^! high-risk v>iants are f\nd almo/ exclusively 9 individuals ( ,african ance/ry1 ,,fsgs contributes to ! disproportionate burd5 ( kidney disease 9 ,black communities2 ,:]eas !re is new hope = pati5ts ) ,,fsgs1 ) cl9ical trials und]way = products t may delay progression ( ,,fsgs & ! onset ( kidney disease1 includ+ ! pot5tial = ,,fda approv$ !rapies 9 ! ne> future1 & significant progress be+ made by sci5ti/s1 regulators1 pati5t gr\ps1 & indu/ry to validate prote9uria z an indicator ( improvem5t 9 pati5ts2 ,:]eas pati5ts1 families1 advocacy organizations l ,neph,cure1 heal? c>e provid]s1 indu/ry1 & rese>*]s are work+ tirelessly to raise aw>5ess1 promote e>ly detection1 & develop new innovative !rapies = ,,fsgs2 ,:]eas millions ( doll>s h be5 rais$ = rese>* on ! sev]e r>e kidney disease ,,fsgs at ! ,tampa ,pig ,jig1 an ev5t />t$ 9 #bjaa :5 #c fri5ds want$ to raise money = a fri5d diagnos$ ) ! r>e kidney disease ,,fsgs & is n[ att5d$ by ab\t #aj1jjj p annually 9 pursuit ( a cure = ?is deva/at+ disease2 & ,:]eas ,,fsgs ,aw>5ess ,day is designat$ to raise aw>5ess ( ,,fsgs1 provide support & inspiration to pati5ts & families /ruggl+ ) ! disease1 & to promote ! ef=ts ne$$ = bett] diagnosis & access to future treatm5ts t c trans=m ! c\rse ( ! disease3 ,n[1 !re=e1 be x ,t ! ,h\se ( ,repres5tatives-- 7#a7 expresses support = ! designation ( ,,fsgs ,aw>5ess ,day2 7#b7 applauds ! ef=ts ( advocates & organizations t enc\rage aw>5ess1 promote rese>*1 & provide education1 support1 & hope to ^? impact$ by ,,fsgs1 includ+ ^? suff]+ f recurr5t ,,fsgs2 & 7#c7 recognizes ! commitm5t ( p>5ts1 families1 rese>*]s1 heal? pr(essionals1 indu/ry1 & o!rs d$icat$ to f9d+ an effective treatm5t & ev5tual cure = ,,fsgs4